Tag: operations

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation

RENO, Nev., June 18, 2025 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA), (the “Company” or “Ormat”), a leading geothermal and renewable energy company, announced today that it has closed its previously disclosed acquisition of the Blue Mountain geothermal power plant from Cyrq Energy. Under the agreement, Ormat paid $88 million for 100% of the equity interest in the 20MW power plant.

AUSTIN, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- EZCORP, Inc. (NASDAQ:EZPW), a leading provider of pawn loans in the United States and Latin America, announced today that it has acquired 40 pawn stores across 13 states in Mexico. The stores, operating under the names “Monte Providencia” and “Tu Empeño Efectivo” offer traditional pawn loans, as well as auto pawn transactions, some of which are in stand-alone auto pawn stores. With this acquisition, the Company also takes over the management of 7 additional Monte Providencia stores, which it plans to acquire in the coming months.

DÜSSELDORF, Germany and ATLANTA, June 18, 2025 (GLOBE NEWSWIRE) -- Heramba Electric plc (OTC: PITEF) announced today the results of an extraordinary shareholder and board meeting held on June 3, 2025. More than 90.0%+ of shareholders voted on the following resolutions:

Statkraft, Europe's largest producer of renewable energy, will further strengthen its core competitive advantages by prioritising its flexible hydropower fleet in the Nordics, industry-leading market operations – and solar, wind and battery activities in Europe and South America. 

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.